Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study to Assess the Tolerability and Pharmacokinetics of APD916 Administered to Healthy Adult Subjects.
Phase of Trial: Phase I
Latest Information Update: 21 Oct 2010
At a glance
- Drugs APD 916 (Primary)
- Indications Cataplexy; Narcolepsy
- Focus Adverse reactions
- 21 Oct 2010 Status changed from recruiting to completed.
- 21 Oct 2010 Results reported in a Arena Pharmaceuticals media release.
- 27 Mar 2010 Official title, lead investigator added as reported by ClinicalTrials.gov.